title: Circulating Apo 2L levels decreased in genotype II hepatitis C with pegylated interferon-2 alpha treatment.
abstract: Pro-inflammatory factors regulated by TRAIL in vivo may lead to the development of novel therapeutic strategies for diseases as diverse as infection, autoimmunity and allergy. In this study we aimed to investigate the relationship between IFN treatment response, HCV viral load and sApo 2L levels. Eleven HCV-treatment naive HCV-infected patients were treated with pegIFN alfa-2a. Intensive serum circulating Apo 2L levels were monitored at study visits on day 0 (pretreatment), and in weeks 4, 6 and 12. HCV-RNA and sApo 2L levels decreased gradually with PegIF-alfa 2 treatment and the differences were significant between day 0 and week 4 (p 0.001, p 0.005 and p 0.01, p 0.005 respectively); between day 0 and week 12 (p 0.001, p 0.005 and p 0.001, p 0.000 respectively); between weeks 6 and 12 (p 0.01, p 0.05 and p 0.01, p 0.05 respectively). We suggest that decreased levels of circulating Apo 2L may reflect its increased binding to its ligand expressed on hepatocytes or lymphocytes under the influence of PegIFN treatment.
authors.affiliation: Department of Allergy and Clinical Immunology, Antalya Training Hospital, Antalya, Turkey; Department of Pathology, Antalya Training Hospital, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Allergy and Clinical Immunology Unit, Tepecik Education and Research Hospital, Izmir, Turkey; Department of Infectious Diseases and Clinical Microbiology, Antalya Education and Research Hospital, Turkey; Department of Medical Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
authors.forename: Arzu Didem
authors.initials: AD
authors.lastname: Yalcin
authors.affiliation: Department of Allergy and Clinical Immunology, Antalya Training Hospital, Antalya, Turkey; Department of Pathology, Antalya Training Hospital, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Allergy and Clinical Immunology Unit, Tepecik Education and Research Hospital, Izmir, Turkey; Department of Infectious Diseases and Clinical Microbiology, Antalya Education and Research Hospital, Turkey; Department of Medical Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
authors.forename: Betul
authors.initials: B
authors.lastname: Celik
authors.affiliation: Department of Allergy and Clinical Immunology, Antalya Training Hospital, Antalya, Turkey; Department of Pathology, Antalya Training Hospital, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Allergy and Clinical Immunology Unit, Tepecik Education and Research Hospital, Izmir, Turkey; Department of Infectious Diseases and Clinical Microbiology, Antalya Education and Research Hospital, Turkey; Department of Medical Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
authors.forename: Sukran
authors.initials: S
authors.lastname: Kose
authors.affiliation: Department of Allergy and Clinical Immunology, Antalya Training Hospital, Antalya, Turkey; Department of Pathology, Antalya Training Hospital, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Allergy and Clinical Immunology Unit, Tepecik Education and Research Hospital, Izmir, Turkey; Department of Infectious Diseases and Clinical Microbiology, Antalya Education and Research Hospital, Turkey; Department of Medical Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
authors.forename: Derya
authors.initials: D
authors.lastname: Seyman
authors.affiliation: Department of Allergy and Clinical Immunology, Antalya Training Hospital, Antalya, Turkey; Department of Pathology, Antalya Training Hospital, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Allergy and Clinical Immunology Unit, Tepecik Education and Research Hospital, Izmir, Turkey; Department of Infectious Diseases and Clinical Microbiology, Antalya Education and Research Hospital, Turkey; Department of Medical Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
authors.forename: Saadet
authors.initials: S
authors.lastname: Gumuslu
authors.affiliation: Department of Allergy and Clinical Immunology, Antalya Training Hospital, Antalya, Turkey; Department of Pathology, Antalya Training Hospital, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Allergy and Clinical Immunology Unit, Tepecik Education and Research Hospital, Izmir, Turkey; Department of Infectious Diseases and Clinical Microbiology, Antalya Education and Research Hospital, Turkey; Department of Medical Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
authors.forename: Ata Nevzat
authors.initials: AN
authors.lastname: Yalcin
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012367:RNA, Viral / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000097:blood* / Q000187:drug effects; D016896:Treatment Outcome; D014421:Turkey; D019562:Viral Load / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a